Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

NCT01145430 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Negative
HER2/Neu Negative
Male Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
Triple-Negative Breast Carcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
OTHER: Pharmacological Study
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)